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ABSTRACT
Aim of the study. Multiple system atrophy (MSA) and spinocerebellar ataxia (SCA) share similar symptomatology. We de-
scribe a rare occurrence of familial MSA that proved to be SCA6 upon genetic analysis. 
Materials and methods. Eighty MSA patients were enrolled in our study; blood samples were collected and genetic screening 
of the familial case for known SCA loci was performed. 
Results. A 68-year-old woman presented with recurrent and severe episodes of light-headedness, imbalance, frequent falls, 
neck and lower back stiffness, subjective arm and leg weakness, and numbness and tingling in both feet. One year later, her 
condition had declined; she experienced more falls, worsening instability, again more generalised but still subjective weakness, 
impaired fine motor movements, slurred speech, difficulty swallowing, episodes of choking, bladder incontinence, and consti-
pation. Clinical suspicion included parkinsonism, MSA, and SCA. The patient was enrolled in our MSA study and was found to 
have 22 and 12 CAG repeats in CACNA1A. The other 79 clinical MSA patients were negative for SCA6 screening.
Conclusions and clinical implications. While MSA and SCA may have similar presentations during early disease stages, the 
presence of both conditions on the list of differential diagnoses can be a diagnostic dilemma. Further analysis will aid in deve-
loping a biomarker to distinguish between the two conditions and guide proper management.
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Introduction
Multiple system atrophy (MSA) and spinocerebellar ataxia 
(SCA) share a similar phenotype, largely due to the involve-
ment of cerebellar degeneration present in both conditions, 
particularly the cerebellar form of MSA [1]. This means that 
differentiating between the two conditions can be challenging. 
SCA is an autosomal dominant neurodegenerative condition 
that affects the cerebellum and spinal cord. More than 45 ge-
netic subtypes of SCA have been identified and listed in the 
Online Mendelian Inheritance in Man database at the National 
Centre for Biotechnology Information. Various types of muta-
tions are known to result in SCA [2–4], including polygluta-
mine CAG repeat expansion. SCA type 6 (SCA6) is caused by 
a CAG trinucleotide repeat in the CACNA1A gene. Possessing 
20 to 33 CAG repeats in 1 allele on CACNA1A has proven to 
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be pathogenic [5–10]. Our genetic analysis demonstrated the 
presence of SCA6 in one familial patient among our cohort 
of 80 patients with MSA.
Materials and methods
Standard protocol approval, patient consent, 
clinical scales/assessments, sample collection 
The study was approved by the Mayo Clinic Institutional 
Review Board, and written informed consent was obtained 
from all participants. Neurological evaluations were perfor-
med by movement disorder specialists at the Mayo Clinic 
Florida, patients were followed clinically by four of the authors 
(J.A.V.G., W.P.C., R.J.U., and Z.K.W.), and all office visits and 
outside records were reviewed. Blood samples were collected 
from all patients. Eighty patients clinically diagnosed with 
MSA were recruited and enrolled, beginning in 1999 and ex-
tending to the present day. The following data was collected: 
date of birth, sex, race, age at enrollment, age at disease onset, 
disease duration, family history of neurological conditions, 
and past medical history. One patient reported a family history 
of parkinsonism reminiscent of MSA (Fig. 1, subject III-2), 
and as a result we screened for several genes to verify whether 
a genetic condition was indeed present. After obtaining the 
results, we decided to screen the remainder of the cohort 
(n = 79). Diagnostic criteria were adopted from the first 
MSA consensus in 1998, consisting of four main domains: 
I Autonomic and Urinary Dysfunction, II Parkinsonism, III 
Cerebellar Dysfunction, and IV Corticospinal Dysfunction, 
and were updated after the second consensus in 2008 [11, 12].
Magnetic resonance imaging
Neuroradiological studies were performed for the index 
case (subject III-2). This included magnetic resonance imaging 
(MRI) scans. All MRI sequences obtained for clinical purposes 
were reviewed (see Supplemental Fig. 1). 
Genetic analysis 
Genomic DNA was extracted from whole blood using 
a FlexSTAR automated extraction machine (AutoGen, Inc) 
according to the manufacturer’s instructions. Whole exome 
sequencing was performed on our familial MSA patient 
using an Agilent SureSelect Human All Exon V5+UTRs 
capture kit, with sequencing performed on an Illumina 
HiSeq2500 by the Mayo Clinic Genomics Core. Exome data 
was processed using the Mayo Genome GPS v4.0 pipeline. 
Functional annotations of variants were performed using 
ANNOVAR (version 2016Feb01). Genotype calls with 
GQ < 10 and/or depth (DP) < 10 were set to missing, and 
variants with ED > 4 were removed from all subsequent 
analyses. For all analyses, only variants that passed Va-
riant Quality Score Recalibration (VQSR) and with a call 
rate > 95% were considered, unless otherwise specified. We 
extracted the identified variants for the SCA-associated 
genes from the generated VCF using Golden Helix (SNP & 
Variation Suite v8.8.3); see Supplemental Table 1. In addi-
tion, we screened nine SCA genes with known pathogenic 
repeats/insertions (again see Supplemental Table 1). The 
regions of interest were amplified (FAM–labelled forward 
primer) using standard polymerase chain reaction (PCR) 
protocol, and the PCR products were run out on an agarose 
gel. The products were diluted based on the intensity of 
the gel image. GeneScan 400HD ROX dye Size Standard 
(Applied Biosystems) was then added to the diluted pro-
duct, which was read on an ABI 3730xl DNA Sequencer 
(Applied Biosystems). Allelic sizes were analysed using 
GeneMapper Software 5 (Applied Biosystems). For Sanger 
sequence validation of pathogenic repeat length, primers 
were designed for the CACNA1A repeat, and the region 
was amplified using standard PCR protocol and cloned 
using a TOPO™ TA Cloning™ Kit (Invitrogen). Products 
were cleaned using Agencourt AMPure XP magnetic beads 
and the Biomek FXP Dual Arm System (Beckman Coulter, 
Inc). The same primers were used for sequencing using 
a BigDye Terminator Cycle Sequencing Kit (Applied Bio-
systems). The cycle sequence products were cleaned with 
Agencourt CleanSEQ magnetic beads (Beckman Coulter, 
Inc) and read on an ABI 3730xl DNA Sequencer. Sequ-
ences were then analysed using SeqScape v3.0 (Applied 
Biosystems) (Fig. 1).
Results
Our proband carried a pathogenic CAG trinucleotide repe-
at in CACNA1A, providing a genetic diagnosis of SCA6 rather 
than MSA. Genetic analysis revealed 22 CAG repeats on 1 allele 
and 12 CAG repeats on a second allele of CACNA1A; the longer 
repeat length was confirmed by Sanger sequencing (Fig. 1). 
Further screening of our clinical MSA series for SCA6 (n = 79) 
did not identify any other carriers of a pathogenic CACNA1A 
repeat length. 
Clinical case description
The patient with SCA6 was a 68-year-old woman with 
a history of aortic regurgitation, arterial hypertension, and 
lacunar infarcts who presented with recurrent and severe 
episodes of light-headedness, gait imbalance, and frequent 
falls. She did not seem to think that her falls were due to the 
chronic dizziness, and cardiovascular work up demonstrated 
aortic regurgitation. She also complained of stiffness in her 
neck and lower back, weakness beginning in the arms then 
involving the legs, and numbness and tingling in both feet. 
She used a walking stick. She noted that her local neurologist 
had diagnosed her with Parkinson’s Disease and administe-
red the regular formulation of carbidopa/levodopa. However 
she was unable to tolerate it due to numbness, tingling, and 
experienced no benefit from it. 
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Her maternal grandmother, mother, and a maternal cousin 
all experienced gait and speech impairment (Fig. 1). 
Neurological evaluation demonstrated nystagmus, slow 
saccades, reduced upgaze, and square wave jerks. Reduced facial 
expression and drooling were absent. She required assistance in 
walking, and her Romberg and pull tests were positive. Stooped 
posture and tremor were absent. Spasticity and hyperreflexia 
were present in the lower extremities. Muscle strength was 
normal in the upper and lower extremities. Two to three beats 
of non-sustained ankle clonus were present, plantar responses 
were positive bilaterally. Formal assessment for orthostatic hy-
potension and autonomic reflex screening were not performed. 
Nerve conduction studies of right motor and sensory me-
dian and ulnar nerves, right tibial, peroneal and sural nerves, 
and needle examination of selected right upper and lower extre-
mity muscles were normal. Amantadine was prescribed, 100mg 
twice a day, and the patient noted a significant improvement in 
her gait and balance. At her second visit 12 months later, the 
patient’s condition had worsened; she had experienced more 
falls and she demonstrated worsening of balance, generalised but 
subjective muscle weakness, impaired fine motor movements, 
slurred speech, difficulty swallowing, and episodes of choking. 
She had also developed urinary stress incontinence treated 
with a pubovaginal sling, as well as constipation. Clinical 
suspicion included parkinsonism based on her generalised 
body bradykinesia.  Probable MSA was considered based 
on the presence of urinary dysfunction, parkinsonism with 
poor levodopa response, and cerebellar dysfunction as per 
the initial MSA consensus [11]. According to the second 
consensus, she fulfilled the criteria for possible MSA due 
to the presence of parkinsonism, cerebellar syndrome, au-
tonomic dysfunction, Babinski sign with hyperreflexia, gait 
ataxia and postural instability [12]. SCA was added to the list 
of differentials due to the presence of gait impairment, fine 
motor dysfunction, in addition to hypophonic and dysarthric 
speech. A more aggressive trial of carbidopa/levodopa was 
administered; one half tablet of 25/100 escalated in half-tablet 
increments each week until reaching 2.5 tablets per dose, three 
times per day. Total daily dose of levadopa was 750mg. The 
patient did not report to the clinic after this point. 
Figure 1. A. Family pedigree of patient with CACNA1A 22 CAG repeats on allele 1, and 12 CAG repeats on allele 2. Pathogenic range is 20 to 33 
CAG repeats. Squares indicate men, circles indicate women; shaded symbols indicate affected individuals. Arrow indicates proband, and slashed 
line through symbol indicates deceased individual. Individual IV-1 developed gait impairment and underwent neurological evaluation by his local 
physician at an outside institution. B. Proband (III-2), peaks identified by fluorescent polymerase chain reaction assay, visualised on GeneMapper 
software, highlighting an expanded repeat. C. Proband (III-2), cloning and sequencing confirmed a 22-repeat allele in the CACNA1A gene
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Head MRI revealed cerebellar atrophy, but no apparent 
pontine atrophy (Supplemental Fig. 1). The patient died 
13 years later. 
The autopsy report, performed at another institution, 
indicated atrophy of the dentate nucleus, substantia nigra, 
inferior olivary nucleus, and cerebellar cortex. Neuronal loss 
was evident in the subthalamic nucleus, globus pallidus, sub-
stantia nigra, and inferior olivary nucleus. Gliosis was present 
in the subthalamic nucleus, basal ganglia, globus pallidus, and 
putamen, and Purkinje cell loss was evident. It is unknown 
whether α-synuclein was present in brain pathology. 
The patient’s eldest son (subject IV-1, Fig. 1) developed 
loss of balance leading to falls at the age of 65; he was evalua-
ted by a local neurologist, exhibited nystagmus and was then 
diagnosed with SCA6. 
Discussion
Familial cases are more rarely encountered in MSA com-
pared to SCA. Some familial forms of MSA have been reported 
previously in the literature. The first was reported in 1964, 
although the diagnosis of MSA is questionable considering 
the lack of pathology and the presence of atypical clinical 
features [13, 14]. When 157 patients with possible and pro-
bable MSA were studied for the presence of family history of 
neurological conditions, only one was found to carry a family 
history of MSA [15]. Autosomal dominant inheritance of MSA 
was reported in a German family [16], and four families were 
reported to have autosomal recessive MSA [17]. This latter 
study discussed the presence of pontine atrophy and 'hot 
cross bun' sign on cranial MRI [17]; however, these findings 
can also be encountered, albeit infrequently, in patients with 
SCA types 2 and 3 [17–19]. While the likelihood of a definitive 
diagnosis of MSA with pontine atrophy and 'hot cross bun' sign 
is decreased by these findings, it should remain a differential 
diagnosis given the reported cases of familial MSA.
Cerebellar ataxia, parkinsonism, pyramidal signs, and 
autonomic dysfunction are signs often shared between MSA 
and SCA patients [20]; while the first condition is sporadic 
and the second is a genetic autosomal dominant disease, both 
fall under spinocerebellar degeneration and exhibit olivopon-
tocerebellar, striatal, and spinal cord involvement [12, 14]. 
Even with its autosomal dominant genetic disposition, there is 
a 15–20% chance that SCA may still occur sporadically, more 
commonly encountered among the trinucleotide forms of SCA 
[12]. Clinically differentiating between the two conditions can 
pose a challenge, especially during the early stages [21]. In 
a review of 203 patients with pathologically confirmed MSA, 
110 (54%) displayed cerebellar ataxia, 98 (49%) pyramidal 
signs, 176 (87%) parkinsonism, and 150 (74%) presented with 
autonomic failure [22]. Parkinsonism was the most frequently 
reported form of motor impairment, followed by cerebellar 
ataxia [22]. Parkinsonism has been previously described in 
SCA6 patients [23], and one patient presented with parkin-
sonism and urinary incontinence and was initially diagnosed 
with MSA [24]. Our patient’s initial symptoms included gait 
impairment, falls, and light-headedness; based on the clinical 
presentation, both SCA and MSA were considered.
In addition to the overlap in symptomatology (Tab. 1), 
disease onset tends to occur later in life with both MSA and 
SCA6 [15, 25]. Mean age at onset for patients with SCA6 is 
43 to 52 years (range 19–71) [5]; therefore, as expected, disease 
progression tends to be slower [6, 26]. This was evident in our 
patient, whose onset of symptoms occurred at 68 years, with 
a disease duration of 15 years. Total lifespan remains unaffected 
in patients with SCA6 [5]. A retrospective analysis investigating 
disease progression and survival rates among different forms 
of cerebellar degenerative disorders revealed that the onset of 
MSA occurs between the ages of 50 and 60, with a median of 
56 years [27]. The study concluded that patients with MSA 
exhibited a faster rate of progression compared to SCA patients. 
Of note, the majority of the patients with SCA in this study 
had SCA type 1, type 2, or type 3; patients with SCA6 were 
not included as a group, given the low sample size (n = 4) [27]. 
Distinguishing MSA from SCA is difficult in clinical pra-
ctice due to the phenotypic overlap. Studies have investigated 
radiological features of MSA and SCA to create a standardised 
protocol in distinguishing the two conditions [1, 21]. However, 
MRI findings commonly associated with MSA, such as the 'hot 
cross bun' sign, hyperintense putaminal rim, and olivoponto-
cerebellar atrophy, can also be encountered with SCA [12, 28]. 
'Hot cross bun' sign and middle cerebellar peduncle hyperin-
tensities were highly specific MRI findings in 12 pathologically 
confirmed MSA cases; they were identified in seven (58.3%) and 
six (50%) of the 12 respectively [29]. Our patient’s MRI findings 
of cerebellar atrophy and lack of pontine involvement point 
Table 1. Clinical characteristics of SCA6 and MSA
SCA6 MSA






















Babinski sign with hyperreflexia
Poor response to levodopa
SCA6 — Spinocerebellar ataxia type 6; MSA — Multiple System Atrophy
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toward a pure cerebellar condition. One study used magnetic 
resonance diffusion kurtosis imaging to monitor and identify 
pathological alterations in patients with cerebellar MSA or SCA, 
concluding that diffusion kurtosis imaging can be used when 
differentiating between the two conditions [1]. Another study 
measured peripheral neurofilament light levels in patients with 
MSA or SCA compared to controls, demonstrating a significant 
increase in neurofilament light levels in those with SCA [30]. 
Perhaps measuring neurofilament light levels could serve 
as a method to distinguish between the two conditions in 
future cases. Early and prompt diagnosis of MSA and SCA 
can improve prognosis, facilitate for better management and 
a more precise therapeutic plan [12, 28].
Genetic counselling is offered to all SCA patients and 
family members. Early detection allows patients planning for 
pregnancy to seek prenatal genetic testing as well as preim-
plantation genetic testing [5].
Our study is limited due to the lack of formal orthostatic and 
autonomic evaluations. However, other signs and symptoms pre-
sent in our patient still point towards MSA as a possible diagnosis. 
MSA and SCA can have similar presentations during early stages, 
and the presence of both conditions on the list of differential diag-
noses can be a common dilemma for clinicians. Further analysis 
will aid in developing a biomarker for longitudinal observations 
and follow up on potential therapies that undoubtedly will be 
developed. Genetic analysis is already widely utilised in SCA 
cases, and it can bring precision to the differential diagnosis. 
Clinical implications/future directions
Despite the rare occurrence of MSA and SCA as differen-
tials, reporting such cases is crucial. Their reporting in the 
literature will provide a stronger incentive to investigate and 
discover blood and cerebrospinal fluid biomarkers that will 
assist in future management. 
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